Finally a decent biotech index! Not as narrowly based as the BTK index, and fewer weird stocks than the current NAS index. People could do a lot worse than just buy the associated ETF.
Nasdaq Announces Component Changes to Biotechnology Index
WASHINGTON, Jan. 22 /PRNewswire/ -- The Nasdaq Stock Market, Inc. today
announced that effective with the market open on Tuesday, January 23, the
components of the Nasdaq Biotechnology Index(R) (NASDAQ:IXBT) will change.
A capitalization-weighted index representing the largest and most actively
traded Nasdaq(R) biotechnology stocks, the Nasdaq Biotech Index includes
companies primarily engaged in using biomedical research for the discovery or
development of novel treatments and cures for human disease. All securities
in the Index must be listed on the Nasdaq National Market(R) and meet minimum
requirements for price, market value, average daily share volume and seasoning
as a public company. In the future, the components will be reviewed
semiannually and changes in the Index will be effective after the close of
trading on the third Friday in May and November.
Nasdaq is undertaking these changes to support a variety of new financial
products. Barclays Global Investors plans to launch an exchange traded fund
(ETF) called the iShares Nasdaq Biotechnology Index Fund on February 2, 2001.
The Index, as of January 23, will include the following 76 companies:
Abgenix, Inc. (NASDAQ:ABGX)
Affymetrix, Inc. (NASDAQ:AFFX)
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)
Alkermes, Inc. (NASDAQ:ALKS)
Amgen Inc. (NASDAQ:AMGN)
Antigenics Inc. (NASDAQ:AGEN)
ArQule, Inc. (NASDAQ:ARQL)
Aurora Biosciences Corporation (NASDAQ:ABSC)
Avigen, Inc. (NASDAQ:AVGN)
Aviron (NASDAQ:AVIR)
Biochem Pharma Inc. (NASDAQ:BCHE)
Biogen, Inc. (NASDAQ:BGEN)
Celgene Corporation (NASDAQ:CELG)
Cell Genesys, Inc. (NASDAQ:CEGE)
Cell Therapeutics, Inc. (NASDAQ:CTIC)
Cephalon, Inc. (NASDAQ:CEPH)
Chiron Corporation (NASDAQ:CHIR)
COR Therapeutics, Inc. (NASDAQ:CORR)
Corixa Corporation (NASDAQ:CRXA)
Corvas International, Inc. (NASDAQ:CVAS)
Cubist Pharmaceuticals, Inc. (NASDAQ:CBST)
CuraGen Corporation (NASDAQ:CRGN)
CV Therapeutics, Inc. (NASDAQ:CVTX)
Dendreon Corporation (NASDAQ:DNDN)
DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA)
Emisphere Technologies, Inc. (NASDAQ:EMIS)
EntreMed, Inc. (NASDAQ:ENMD)
Enzon, Inc. (NASDAQ:ENZN)
Exelixis, Inc. (NASDAQ:EXEL)
Gene Logic Inc. (NASDAQ:GLGC)
Generex Biotechnology Corporation (NASDAQ:GNBT)
Genzyme General (NASDAQ:GENZ)
Geron Corporation (NASDAQ:GERN)
Gilead Sciences, Inc. (NASDAQ:GILD)
Guilford Pharmaceuticals Inc. (NASDAQ:GLFD)
Human Genome Sciences, Inc. (NASDAQ:HGSI)
ICOS Corporation (NASDAQ:ICOS)
IDEC Pharmaceuticals Corporation (NASDAQ:IDPH)
ImClone Systems Incorporated (NASDAQ:IMCL)
Immunex Corporation (NASDAQ:IMNX)
ImmunoGen, Inc. (NASDAQ:IMGN)
Incyte Genomics Inc. (NASDAQ:INCY)
Inhale Therapeutic Systems, Inc. (NASDAQ:INHL)
InterMune Pharmaceuticals, Inc. (NASDAQ:ITMN)
Isis Pharmaceuticals, Inc. (NASDAQ:ISIP)
Kos Pharmaceuticals, Inc. (NASDAQ:KOSP)
Lexicon Genetics Incorporated (NASDAQ:LEXG)
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Luminex Corporation (NASDAQ:LMNX)
Matrix Pharmaceutical, Inc. (NASDAQ:MATX)
Medarex, Inc. (NASDAQ:MEDX)
MedImmune, Inc. (NASDAQ:MEDI)
Millennium Pharmaceuticals, Inc. (NASDAQ:MLNM)
Myriad Genetics, Inc. (NASDAQ:MYGN)
NeoPharm, Inc. (NASDAQ:NEOL)
Neurocrine Biosciences, Inc. (NASDAQ:NBIX)
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP)
ONYX Pharmaceuticals, Inc. (NASDAQ:ONXX)
OSI Pharmaceuticals Inc. (NASDAQ:OSIP)
PRAECIS PHARMACEUTICALS INC. (NASDAQ:PRCS)
Progenics Pharmaceuticals Inc. (NASDAQ:PGNX)
Protein Design Labs, Inc. (NASDAQ:PDLI)
QLT Inc. (NASDAQ:QLTI)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Ribozyme Pharmaceuticals, Inc. (NASDAQ:RZYM)
Sangamo BioSciences, Inc. (NASDAQ:SGMO)
Scios, Inc. (NASDAQ:SCIO)
SuperGen, Inc. (NASDAQ:SUPG)
Tanox, Inc. (NASDAQ:TNOX)
Transkaryotic Therapies, Inc. (NASDAQ:TKTX)
Trimeris, Inc. (NASDAQ:TRMS)
Tularik Inc. (NASDAQ:TLRK)
United Therapeutics Corporation (NASDAQ:UTHR)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Vical Incorporated (NASDAQ:VICL)
ViroPharma Incorporated (NASDAQ:VPHM)
The Nasdaq Biotechnology Index, launched in November 1993, rose 23 percent
in 2000, although past performance is not necessarily indicative of future
performance. For more information about the Nasdaq Biotechnology Index,
including eligibility criteria, visit: nasdaq.com .
The Nasdaq Stock Market(R) lists nearly 5,000 companies, has the largest
dollar volume of trades of any financial market, and trades more shares per
day than any other U.S. market. Current market capitalization is $3.6
trillion. Nasdaq is a subsidiary of the NASD, the largest securities-industry,
self-regulatory organization in the United States. For more information about
Nasdaq, visit the Nasdaq Web site at nasdaq.com or the Nasdaq
Newsroom(SM) at nasdaqnews.com .
SOURCE The Nasdaq Stock Market
-0- 01/22/2001
/CONTACT: Judith Inosanto, 202-728-8243, or Kate Mitchel, 202-496-2627,
both of the Nasdaq Stock Market/
/Web site: nasdaqnews.com
nasdaq.com;
Peter |
